<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Khan M</submitter><funding>Deanship of Scientific Research, King Khalid University</funding><pagination>e23323</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10757017</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(1)</volume><pubmed_abstract>Inhibiting α-glucosidase is a reliable method for reducing blood sugar levels in diabetic individuals. &lt;i>Bis&lt;/i>(dimethylamino)benzophenone derivatives &lt;b>1&lt;/b>-&lt;b>27&lt;/b> were synthesized from &lt;i>bis&lt;/i>(dimethylamino)benzophenone via two-step reaction. Different spectroscopic techniques, including EI-MS and 1H NMR, were employed to characterize all synthetic derivatives. The elemental composition of synthetic compounds was confirmed by elemental analysis and results were found in agreement with the calculated values. The synthetic compounds &lt;b>1&lt;/b>-&lt;b>27&lt;/b> were evaluated for &lt;i>α&lt;/i>-glucosidase inhibitory activity, except five compounds all derivatives showed good to moderate inhibitory potential in the range of IC&lt;sub>50&lt;/sub> = 0.28 ± 2.65 - 0.94 ± 2.20 μM. Among them, the most act</pubmed_abstract><journal>Heliyon</journal><pubmed_title>Synthesis of new &lt;i>bis&lt;/i>(dimethylamino)benzophenone hydrazone for diabetic management: &lt;i>In-vitro&lt;/i> and &lt;i>in-silico&lt;/i> approach.</pubmed_title><pmcid>PMC10757017</pmcid><funding_grant_id>2/100/44</funding_grant_id><pubmed_authors>Ahad G</pubmed_authors><pubmed_authors>Khan A</pubmed_authors><pubmed_authors>Kanwal</pubmed_authors><pubmed_authors>Khan KM</pubmed_authors><pubmed_authors>Uddin J</pubmed_authors><pubmed_authors>Salar U</pubmed_authors><pubmed_authors>Al-Harrasi A</pubmed_authors><pubmed_authors>Alam A</pubmed_authors><pubmed_authors>Perveen S</pubmed_authors><pubmed_authors>Ullah S</pubmed_authors><pubmed_authors>Ajmal A</pubmed_authors><pubmed_authors>Khan M</pubmed_authors><pubmed_authors>Wadood A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Synthesis of new &lt;i>bis&lt;/i>(dimethylamino)benzophenone hydrazone for diabetic management: &lt;i>In-vitro&lt;/i> and &lt;i>in-silico&lt;/i> approach.</name><description>Inhibiting α-glucosidase is a reliable method for reducing blood sugar levels in diabetic individuals. &lt;i>Bis&lt;/i>(dimethylamino)benzophenone derivatives &lt;b>1&lt;/b>-&lt;b>27&lt;/b> were synthesized from &lt;i>bis&lt;/i>(dimethylamino)benzophenone via two-step reaction. Different spectroscopic techniques, including EI-MS and 1H NMR, were employed to characterize all synthetic derivatives. The elemental composition of synthetic compounds was confirmed by elemental analysis and results were found in agreement with the calculated values. The synthetic compounds &lt;b>1&lt;/b>-&lt;b>27&lt;/b> were evaluated for &lt;i>α&lt;/i>-glucosidase inhibitory activity, except five compounds all derivatives showed good to moderate inhibitory potential in the range of IC&lt;sub>50&lt;/sub> = 0.28 ± 2.65 - 0.94 ± 2.20 μM. Among them, the most act</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jan</publication><modification>2026-05-29T02:10:41.79Z</modification><creation>2025-02-18T23:26:18.02Z</creation></dates><accession>S-EPMC10757017</accession><cross_references><pubmed>38163112</pubmed><doi>10.1016/j.heliyon.2023.e23323</doi></cross_references></HashMap>